Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus
Küçük Resim Yok
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Verduci Publisher
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
OBJECTIVE: Obesity and Type 2 diabetes mellitus are growing health problems all over the world. The aim of this study is the comparison of 3 mg liraglutide and metformin combination, metformin monotherapy on the blood glucose regulation, weight loss and lipid panel in the patients with Type 2 diabetes melli-tus whose BMI is >= 30 kg/m(2). PATIENTS AND METHODS: 276 patients in-cluded in the study were divided into two groups (1:1); liraglutide (3 mg) + metformin combination (L+M) and metformin monotherapy (M) (2x1,000 mg) (exercise and diet were regulated in both groups). Patients' body composition measure-ments were performed and fasting blood glu-cose, postprandial blood glucose, HbA1c, tri-glyceride, total cholesterol, LDL, HDL levels were measured by TANITA device prior to the therapy and in the week 12 of the therapy. RESULTS: The average age of 276 patients included in the study was 49.70 +/- 7.93 years. A statistically significant decrease was noted in weight, BMI, fasting blood glucose, postprandi-al blood glucose, HbA1c values of both groups at the end of the third month. 11.3 kg of weight was lost on average in L+M group (-12.3%); 4.5 kg of weight was lost in the monotherapy group (-4.9%). A decrease of 14.3% was seen in the body fat mass, 2.1% in the muscle mass in L+M group and a decrease of 4.4% in the body fat mass and 6.1% in the muscle mass in the mono -therapy group. The decrease in the body fat was higher at a statistically significant level in L+M group and the decrease in the muscle mass was higher in the monotherapy group. HbA1c de-creased by 17.9% in L+M group (-1.49 +/- 0.46, Co-hen's d=2.68), 5.3% in the monotherapy group (-0.37 +/- 0.26, Cohen's d=0.90). The decrease in TG, total cholesterol, LDL was higher at a sta-tistically significant level in L+M group. The increase in HDL level was higher in the mono -therapy group (L+M=22.7%, M=35.4%). A weight loss that was over 10% occurred in 4.3% of the patients in the monotherapy group and 68.1% of the combined therapy group at the end of 12 weeks (95% C.I. OR=19.49-121.65). CONCLUSIONS: The effect of the combination of liraglutide 3 mg and metformin on blood glu-cose regulation, weight loss (fat loss, muscle conservation) was found to be superior to the metformin monotherapy in the obese patients with Type 2 diabetes mellitus according to the early period results.
Açıklama
Anahtar Kelimeler
Diabetes, Obesity, Metformin, Liraglutide
Kaynak
European Review For Medical and Pharmacological Sciences
WoS Q Değeri
Q2
Scopus Q Değeri
Cilt
26
Sayı
18
